Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.44 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498399 | 0.78 | KDM4E (0.52) | VNN1GRIN2B | |
| SCHEMBL6507154 | 0.77 | DRD2 (0.59) | DRD2DRD3NOTUMCHRM4SLC2A1 | |
| SCHEMBL6445604 | 0.74 | MGLL (0.58) | DRD2DRD3NOTUMCHRM4 | |
| SCHEMBL6497130 | 0.73 | NOTUM (0.48) | DRD2DRD3NOTUMGRM5TP53 | |
| SCHEMBL6498980 | 0.73 | NOTUM (0.48) | DRD2DRD3NOTUMGRM5TP53 | |
| SCHEMBL15800697 | 0.72 | DRD2 (0.79) | DRD2DRD3NOTUMSLC2A1SLC2A2 | |
| SCHEMBL3051168 | 0.72 | DRD2 (0.64) | DRD2DRD3NOTUMCHRM4SLC2A1 | |
| SCHEMBL2732722 | 0.72 | DRD2 (0.64) | DRD2DRD3NOTUMCHRM4SLC2A1 | |
| SCHEMBL12367085 | 0.72 | DRD2 (0.64) | DRD2DRD3NOTUMCHRM4SLC2A1 | |
| SCHEMBL25080895 | 0.72 | BPTF (0.64) | DRD2DRD3NOTUMCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | VNN1 1029/4885DRD2 796/4885DRD3 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.